Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18509
Country/Region: Kenya
Year: 2018
Main Partner: Amref Health Africa
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $2,363,795 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $162,543
Care: Pediatric Care and Support (PDCS) $0
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $263,827
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $313,781
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $1,596,851
Treatment: Pediatric Treatment (PDTX) $26,793
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2019 3
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV <10, Male, Physical and/or Emotional Violence 2019 3
GEND_GBV <10, Male, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2019 11
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 11
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2019 3
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2019 37
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 37
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2019 3
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2019 51
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 53
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2019 3
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV 25-29, Female, Physical and/or Emotional Violence 2019 10
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 11
GEND_GBV 25-29, Male, Physical and/or Emotional Violence 2019 3
GEND_GBV 25-29, Male, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV 30-34, Female, Physical and/or Emotional Violence 2019 10
GEND_GBV 30-34, Female, Sexual Violence (Post-Rape Care) 2019 11
GEND_GBV 30-34, Male, Physical and/or Emotional Violence 2019 3
GEND_GBV 30-34, Male, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV 35-39, Female, Physical and/or Emotional Violence 2019 10
GEND_GBV 35-39, Female, Sexual Violence (Post-Rape Care) 2019 11
GEND_GBV 35-39, Male, Physical and/or Emotional Violence 2019 3
GEND_GBV 35-39, Male, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV 40-49, Female, Physical and/or Emotional Violence 2019 10
GEND_GBV 40-49, Female, Sexual Violence (Post-Rape Care) 2019 11
GEND_GBV 40-49, Male, Physical and/or Emotional Violence 2019 3
GEND_GBV 40-49, Male, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2019 3
GEND_GBV 50+, Female, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV 50+, Male, Physical and/or Emotional Violence 2019 5
GEND_GBV 50+, Male, Sexual Violence (Post-Rape Care) 2019 5
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 45
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 178
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 178
GEND_GBV Number of people receiving post-GBV care 2019 355
HTS_SELF 2019 436
HTS_SELF 15-19, Female, Directly-Assisted 2019 23
HTS_SELF 15-19, Female, Unassisted 2019 23
HTS_SELF 15-19, Male, Directly-Assisted 2019 8
HTS_SELF 15-19, Male, Unassisted 2019 8
HTS_SELF 20-24, Female, Directly-Assisted 2019 23
HTS_SELF 20-24, Female, Unassisted 2019 23
HTS_SELF 20-24, Male, Directly-Assisted 2019 8
HTS_SELF 20-24, Male, Unassisted 2019 8
HTS_SELF 25-29, Female, Directly-Assisted 2019 23
HTS_SELF 25-29, Female, Unassisted 2019 23
HTS_SELF 25-29, Male, Directly-Assisted 2019 8
HTS_SELF 25-29, Male, Unassisted 2019 8
HTS_SELF 30-34, Female, Directly-Assisted 2019 23
HTS_SELF 30-34, Female, Unassisted 2019 23
HTS_SELF 30-34, Male, Directly-Assisted 2019 8
HTS_SELF 30-34, Male, Unassisted 2019 8
HTS_SELF 35-39, Female, Directly-Assisted 2019 23
HTS_SELF 35-39, Female, Unassisted 2019 23
HTS_SELF 35-39, Male, Directly-Assisted 2019 8
HTS_SELF 35-39, Male, Unassisted 2019 8
HTS_SELF 40-49, Female, Directly-Assisted 2019 23
HTS_SELF 40-49, Female, Unassisted 2019 23
HTS_SELF 40-49, Male, Directly-Assisted 2019 8
HTS_SELF 40-49, Male, Unassisted 2019 8
HTS_SELF 50+, Female, Directly-Assisted 2019 23
HTS_SELF 50+, Female, Unassisted 2019 23
HTS_SELF 50+, Male, Directly-Assisted 2019 8
HTS_SELF 50+, Male, Unassisted 2019 8
HTS_SELF Directly-Assisted 2019 218
HTS_SELF FSW, Directly-Assisted 2019 291
HTS_SELF MSM, Directly-Assisted 2019 65
HTS_SELF PWID, Directly-Assisted 2019 26
HTS_SELF Unassisted 2019 218
HTS_SELF Unassisted - Other 2019 22
HTS_SELF Unassisted - Self 2019 109
HTS_SELF Unassisted - Sex Partner 2019 87
HTS_TST 15-19, Female, Negative 2019 12
HTS_TST 15-19, Male, Negative 2019 7
HTS_TST 20-24, Female, Negative 2019 45
HTS_TST 20-24, Male, Negative 2019 23
HTS_TST 25-29, Female, Negative 2019 219
HTS_TST 25-29, Female, Negative 2019 527
HTS_TST 25-29, Female, Negative 2019 948
HTS_TST 25-29, Female, Negative 2019 4
HTS_TST 25-29, Female, Negative 2019 19
HTS_TST 25-29, Female, Negative 2019 118
HTS_TST 25-29, Male, Negative 2019 360
HTS_TST 25-29, Male, Negative 2019 1,091
HTS_TST 25-29, Male, Negative 2019 6
HTS_TST 25-29, Male, Negative 2019 25
HTS_TST 25-29, Male, Negative 2019 143
HTS_TST 30-34, Female, Negative 2019 250
HTS_TST 30-34, Female, Negative 2019 610
HTS_TST 30-34, Female, Negative 2019 948
HTS_TST 30-34, Female, Negative 2019 4
HTS_TST 30-34, Female, Negative 2019 16
HTS_TST 30-34, Female, Negative 2019 136
HTS_TST 30-34, Male, Negative 2019 432
HTS_TST 30-34, Male, Negative 2019 1,297
HTS_TST 30-34, Male, Negative 2019 7
HTS_TST 30-34, Male, Negative 2019 27
HTS_TST 30-34, Male, Negative 2019 176
HTS_TST 35-39, Female, Negative 2019 62
HTS_TST 35-39, Female, Negative 2019 166
HTS_TST 35-39, Female, Negative 2019 948
HTS_TST 35-39, Female, Negative 2019 1
HTS_TST 35-39, Female, Negative 2019 20
HTS_TST 35-39, Female, Negative 2019 34
HTS_TST 35-39, Male, Negative 2019 432
HTS_TST 35-39, Male, Negative 2019 1,242
HTS_TST 35-39, Male, Negative 2019 7
HTS_TST 35-39, Male, Negative 2019 37
HTS_TST 35-39, Male, Negative 2019 176
HTS_TST 40-49, Female, Negative 2019 62
HTS_TST 40-49, Female, Negative 2019 166
HTS_TST 40-49, Female, Negative 2019 948
HTS_TST 40-49, Female, Negative 2019 1
HTS_TST 40-49, Female, Negative 2019 16
HTS_TST 40-49, Female, Negative 2019 34
HTS_TST 40-49, Male, Negative 2019 144
HTS_TST 40-49, Male, Negative 2019 415
HTS_TST 40-49, Male, Negative 2019 2
HTS_TST 40-49, Male, Negative 2019 34
HTS_TST 40-49, Male, Negative 2019 59
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 42,969
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2019 4
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 531
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 2,337
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2019 146
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 409
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 97
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 84
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 799
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 419
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 2,752
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 2,677
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 31
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 72
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 168
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 40
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 34
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 1,693
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 1,808
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 8,010
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 3,768
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 83
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 207
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 674
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 11
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 13
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 13
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 19
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 22
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 20
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 25
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 16
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 28
HTS_TST Service Delivery Point (Facility) VCT: <1, Negative 2019 6
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2019 31
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2019 6
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2019 8
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 302
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 183
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 1,043
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 586
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 17
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 30
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2019 60
HTS_TST_POS 20-24, Female, Positive 2019 1
HTS_TST_POS 25-29, Female, Positive 2019 5
HTS_TST_POS 25-29, Female, Positive 2019 19
HTS_TST_POS 25-29, Female, Positive 2019 135
HTS_TST_POS 25-29, Female, Positive 2019 4
HTS_TST_POS 25-29, Female, Positive 2019 1
HTS_TST_POS 25-29, Male, Positive 2019 8
HTS_TST_POS 25-29, Male, Positive 2019 38
HTS_TST_POS 25-29, Male, Positive 2019 4
HTS_TST_POS 30-34, Female, Positive 2019 7
HTS_TST_POS 30-34, Female, Positive 2019 21
HTS_TST_POS 30-34, Female, Positive 2019 4
HTS_TST_POS 30-34, Female, Positive 2019 3
HTS_TST_POS 30-34, Female, Positive 2019 2
HTS_TST_POS 30-34, Male, Positive 2019 8
HTS_TST_POS 30-34, Male, Positive 2019 44
HTS_TST_POS 30-34, Male, Positive 2019 4
HTS_TST_POS 30-34, Male, Positive 2019 3
HTS_TST_POS 35-39, Female, Positive 2019 1
HTS_TST_POS 35-39, Female, Positive 2019 6
HTS_TST_POS 35-39, Female, Positive 2019 3
HTS_TST_POS 35-39, Female, Positive 2019 4
HTS_TST_POS 35-39, Male, Positive 2019 8
HTS_TST_POS 35-39, Male, Positive 2019 43
HTS_TST_POS 35-39, Male, Positive 2019 7
HTS_TST_POS 35-39, Male, Positive 2019 3
HTS_TST_POS 40-49, Female, Positive 2019 1
HTS_TST_POS 40-49, Female, Positive 2019 6
HTS_TST_POS 40-49, Female, Positive 2019 2
HTS_TST_POS 40-49, Female, Positive 2019 3
HTS_TST_POS 40-49, Male, Positive 2019 1
HTS_TST_POS 40-49, Male, Positive 2019 14
HTS_TST_POS 40-49, Male, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 9
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 67
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 17
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 50
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 31
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Other PITC: <1, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 58
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 65
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 283
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 131
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) TB: 1-9, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Female, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 21
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 11
PMTCT_ART Already on ART at beginning of current pregnancy 2019 530
PMTCT_ART New on ART 2019 209
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 739
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 7,358
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 22
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 22
PMTCT_EID Sum of Infant Age disaggregates 2019 22
PMTCT_STAT 25-29, Female 2019 1,076
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 104
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 937
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 32
PMTCT_STAT 30-34, Female 2019 1,076
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 104
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 937
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 32
PMTCT_STAT 35-39, Female 2019 1,076
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 104
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 937
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 32
PMTCT_STAT 40-49, Female 2019 1,076
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 104
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 937
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 32
PMTCT_STAT By Age (Numerator): 10-14 2019 4
PMTCT_STAT By Age (Numerator): 15-19 2019 569
PMTCT_STAT By Age (Numerator): 20-24 2019 2,485
PMTCT_STAT By Age (Numerator): 50+ 2019 1
PMTCT_STAT By Number of known positives: 15-19 2019 20
PMTCT_STAT By Number of known positives: 20-24 2019 113
PMTCT_STAT By Number of known positives: 50+ 2019 1
PMTCT_STAT By Number of new negative: 10-14 2019 4
PMTCT_STAT By Number of new negative: 15-19 2019 527
PMTCT_STAT By Number of new negative: 20-24 2019 2,314
PMTCT_STAT By Number of new positives: 15-19 2019 18
PMTCT_STAT By Number of new positives: 20-24 2019 78
PMTCT_STAT Number of new ANC and L&D clients 2019 7,514
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 7,358
PMTCT_STAT_den 25-29, Female 2019 1,077
PMTCT_STAT_den 30-34, Female 2019 1,077
PMTCT_STAT_den 35-39, Female 2019 1,077
PMTCT_STAT_den 40-49, Female 2019 1,077
PMTCT_STAT_den By Age (Denominator): <15-19 2019 638
PMTCT_STAT_den By Age (Denominator): 10-14 2019 4
PMTCT_STAT_den By Age (Denominator): 20-24 2019 2,564
PrEP_NEW 25-29, Female 2019 9
PrEP_NEW 25-29, Male 2019 4
PrEP_NEW 30-34, Female 2019 7
PrEP_NEW 30-34, Male 2019 7
PrEP_NEW 35-39, Female 2019 7
PrEP_NEW 35-39, Male 2019 17
PrEP_NEW 40-49, Female 2019 10
PrEP_NEW 40-49, Male 2019 6
PrEP_NEW Female 15-19 2019 21
PrEP_NEW Female 20-24 2019 121
PrEP_NEW Female 50+ 2019 4
PrEP_NEW Male 15-19 2019 1
PrEP_NEW Male 20-24 2019 8
PrEP_NEW Male 50+ 2019 4
PrEP_NEW Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2019 225
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 53
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 69
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 122
TB_PREV By Age/Sex (Numerator): <15, Female 2019 58
TB_PREV By Age/Sex (Numerator): <15, Male 2019 65
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 1,059
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 560
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 1,740
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 2,121
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 75
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 79
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 1,286
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 680
TB_PREV_den IPT, Life-long ART, New, Positive 2019 2,121
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 14
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 161
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 17
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 244
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 436
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 423
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 14
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 155
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 16
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 239
TX_CURR 25-29, Female, Positive 2019 2,217
TX_CURR 25-29, Male, Positive 2019 672
TX_CURR 30-34, Female, Positive 2019 1,682
TX_CURR 30-34, Male, Positive 2019 1,050
TX_CURR 35-39, Female, Positive 2019 1,682
TX_CURR 35-39, Male, Positive 2019 1,051
TX_CURR 40-49, Female, Positive 2019 1,146
TX_CURR 40-49, Male, Positive 2019 1,051
TX_CURR Age/Sex: <1 2019 10
TX_CURR Age/Sex: <1-9 2019 282
TX_CURR Age/Sex: 10-14 Female 2019 157
TX_CURR Age/Sex: 10-14 Male 2019 151
TX_CURR Age/Sex: 15-19 Female 2019 352
TX_CURR Age/Sex: 15-19 Male 2019 189
TX_CURR Age/Sex: 20-24 Female 2019 978
TX_CURR Age/Sex: 20-24 Male 2019 254
TX_CURR Age/Sex: 50+ Female 2019 915
TX_CURR Age/Sex: 50+ Male 2019 378
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 14,220
TX_CURR Sum of age/sex disaggregates 2019 541
TX_NEW 25-29, Female, Positive 2019 45
TX_NEW 25-29, Male, Positive 2019 80
TX_NEW 30-34, Female, Positive 2019 52
TX_NEW 30-34, Male, Positive 2019 97
TX_NEW 35-39, Female, Positive 2019 15
TX_NEW 35-39, Male, Positive 2019 97
TX_NEW 40-49, Female, Positive 2019 15
TX_NEW 40-49, Male, Positive 2019 33
TX_NEW Breastfeeding status 2019 11
TX_NEW By Age/Sex: <1 2019 21
TX_NEW By Age/Sex: 1-9 2019 12
TX_NEW By Age/Sex: 10-14 Female 2019 2
TX_NEW By Age/Sex: 10-14 Male 2019 2
TX_NEW By Age/Sex: 15-19 Female 2019 178
TX_NEW By Age/Sex: 15-19 Male 2019 90
TX_NEW By Age/Sex: 20-24 Female 2019 615
TX_NEW By Age/Sex: 20-24 Male 2019 290
TX_NEW By Age/Sex: 50+ Female 2019 5
TX_NEW By Age/Sex: 50+ Male 2019 16
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 1,664
TX_NEW Pregnancy status 2019 199
TX_NEW Sum of Age/Sex disaggregates 2019 1,198
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 15,511
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 157
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 48
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 151
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 42
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 8,342
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 1,302
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 4,646
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 822
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 31
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 23
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 1,694
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 717
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 2,468
TX_RET Numerator by Status: Breastfeeding 2019 41
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 2,550
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 32
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 24
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 1,727
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 767
TX_RET_den Denominator by Status: Breastfeeding 2019 34
TX_RET_den Denominator by Status: Pregnant 2019 231
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 14,220
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 371
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 361
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 9,192
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 4,298
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 290
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 129
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 436
Cross Cutting Budget Categories and Known Amounts Total: $282,000
Gender: Gender Based Violence (GBV) $6,760
GBV Prevention
Implementation
Capacity building
Post GBV Care
Implementation
Capacity building
Human Resources for Health $275,240